Conference Reports for NATAP

Back

19th European AIDS Conference October 18th-21st , 2023 Warsaw, Poland     Effect of doravirine on body weight and body mass index in treatment naïve adults with HIV-1 - (12/20/23)   Efficacy and safety of topical trichloroacetic acid vs. electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive patients (TECAIN) - a randomized controlled trial - (12/20/23)   To the liver and beyond: the impact of HCV clearance with direct antiviral agents in people living with HIV/HCV - (11/8/23)   The status of hepatitis C micro-elimination among people living with HIV in Central and Eastern Europe in 2022 - data from Euroguidelines in Central and Eastern Europe Network Group - (11/8/23)   Impact of directly acting-antivirals and behaviour change on HCV micro-elimination in MSM due to the COVID 19 pandemic in Germany - Results from the NoCo cohort - (11/8/23)   Frailty Accelerates Aging/Mortality: INTEGRATE Care for Older PWH Integrating [differential] approaches to older people living with HIV - (11/06/23)   COVID-19 Associated with 35% Increased Risk for Major Cardiovascular events in PWH During Subsequent Yea - (11/06/23)   Despite Very Early ART Inflammation is Reduced But Persists - (11/06/23)   Mental health disorders in people living with HIV - (11/06/23)   Early Onset Frailty in PWH at UK Silver Clinic; Implementation of Frailty Screening - (11/06/23)   HIV in the elderly is becoming an easily manageable pathology: reality is contradictory. Much More Complex - (11/06/23)   Virus-Related and AIDS Cancer Incidence Fell in HIV Group But Still Exceed Rates in General Population - (10/31/23)   Factors influencing discontinuation of care of women seeking Pre-Exposure Prophylaxis (PrEP) - (10/31/23)   Doravirine Does Not Drive up ASCVD Risk Through 4 Years - Mark Mascolini (10/31/23)   Temporal trends and impact of COVID-19 on the HIV cascade of care across Europe between 2016-2021 - Mark Mascolini (10/31/23)   One in Eight Amsterdam ART Responders May Have PTSD - Mark Mascolini (10/31/23)   Total and LDL Cholesterol Climb After HCV Cure in People With HIV - Mark Mascolini (10/26/23)   HDV Prevalence 16% in French Group With HBV and HIV - Mark Mascolini (10/26/23)   In 70 and Older HIV Group, Frailty Worsens in Some, Improves in Others - Mark Mascolini (10/26/23)   Classic Fracture Risk Factors May Need Replacing in Older People With HIV - Mark Mascolini (10/26/23)   Weight gain and loss and stable weight in relation to fat and lean mass in PWH - (10/26/23)   Early and Durable Reductions in Soluble CD14 Concentrations Among Treatment-Experienced Persons With HIV-1 Through 96 Weeks of Fostemsavir Treatment in a Phase 2b Clinical Trial - (10/26/23)   Bictegravir alters glucose tolerance and metabolism - (10/26/23)   Persistent Low-Level Viremia May Increase Risk of Cardiovascular Disorders in PWH - (10/26/23)   Lessons from the Swiss Cohort study: Metabolic and cardiovascular co-morbidities among people living with HIV - (10/26/23)   Single center study on participants living with HIV with isolated anticore antibody (anti-HBc) switching to long acting cabotegravir-rilpivirine therapy: Results from the SCohoLART study - (10/25/23)   Long-Acting CAB + RPV Fails With Resistance in 5 After Long Control on Oral Regimens - Mark Mascolini (10/25/23)   Failure Rate Similar With Long-Acting CAB + RPV and Standard Oral Combos - Mark Mascolini (10/25/23)   Fostemsavir use in the OPERA cohort: immunologic and virologic response - (10/25/23)   EFFICACY AND DURABILITY OF FOSTEMSAVIR, IBALIZUMAB, OR LENACAPAVIR-INCLUDING REGIMENS IN PEOPLE LIVING WITH MULTIDRUG-RESISTANT HIV-1: RESULTS FROM THE PRESTIGIO REGISTRY - (10/25/23)   FOSTEMSAVIR IN ASSOCIATION WITH DORAVIRINE FOR THE TREATMENT OF HEAVILY TREATMENT-EXPERIENCED (HTE) PLWH WITH MULTI-DRUG RESISTANT (MDR) HIV-1 INFECTION: DATA FROM CLINICAL PRACTICE - (10/25/23)   How to choose the optimized background therapy with fostemsavir in viremic people with multidrug-resistant HIV? A clinical case - (10/25/23)   Long-term Safety and Impact of Immune Recovery in Heavily Treatment-Experienced Adults Receiving Fostemsavir for up to 5 Years in the BRIGHTE Study - (10/25/23)   Real-world Effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naive People With HIV-1 and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review - (10/25/23)   Systematic Literature Review of Real-world Experience With the 2-Drug Regimen Dolutegravir + Lamivudine (DTG + 3TC) in People With HIV-1 Aged ≥50 Years - (10/25/23)   Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir: The DOLOMITE-EPPICC Study - (10/25/23)   One Third of French Group Has Not Changed Antiretrovirals for Over 10 Years - Mark Mascolini (10/25/23)   Real-world retrospective observational study on the use of Doravirine (DOR) based regimens in clinical practice in Europe - (10/25/23)   Annual Antiretroviral Switch Rate Jumps From 8% to 18% in Last Decade - Mark Mascolini (10/24/23)   HBcAb positivity is a risk factor for failure to achieve complete virologic suppression of HIV-RNA after antiretroviral switch to 3TC+DTG - Mark Mascolini (10/24/23)   Real-world 2-year weight changes among people with sustained HIV suppression: a multicenter French retrospective cohort study - Mark Mascolini (10/24/23)   Cabotegravir/rilpivirine based long acting therapy with insufficient drug levels in routine drug monitoring - Mark Mascolini (10/24/23)   Non-AIDS Non-Hepatitis Cancers Lead Causes of Death With HIV in Switzerland - Mark Mascolini (10/24/23)   Effect of ART, Immunologic-virologic status and Prior TB on Mortality Among People with HIV in Europe - (10/24/23)   Switch to Fixed-Dose Doravirine/Islatravir (100/0.75 mg) Once Daily in Adults with HIV-1 Virologically Suppressed on Biktarvy - week 96 results of a phase 3, randomized, double-blind, non-inferiority trial - (10/24/23)   Below 200 Relevance of low-Level Viremia (50-200) in Participants on ART in the Swiss HV Cohort Study - (10/24/23)   Prevalence and Clinical Impact of Doravirine-associated Resistance Mutations in a Real-World Population of NNRTI-Naive and NNRTI-Experience Individuals - (10/24/23)   Failure Following Switch from Long-Term Suppressive Oral ART to Long Acting Cabotegravir/Rilpivirine injections - (10/24/23)   Effectiveness of LA Injectable Cabotegravir+Rilpivirine for the Treatment of HIV-1: results from the Dutch Athena national observation cohort - (10/24/23)   Uptake/Discontinuation of LA CAB/RPV Swiss HIV Cohort - (10/24/23)   Sustained Improvements in Biomarkers Observed With Fostemsavir in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 From the Phase 3 BRIGHTE Study Through Week 240 - (10/24/23)   Persistent Low-Level Viremia Leads to Immune T-cell Exhaustion in PLWH - (10/24/23)   A Screening Tool as Part of Routine Clinical Care Detects Post Traumatic Syndrome (PTSD) Symptoms in PWH - (10/24/23)   Drivers of Discontinuation of Oral PrEP Within Europe: Findings From a Real-World Survey of PrEP Use - (10/24/23)   Early virologic failure with Cabotegravir plus Rilpivirine in clinical practice - (10/24/23)   Integrase inhibitor as cause of drug induced liver injury - (10/24/23)   Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + 2 NRTIs in Treatment-Naive Adults: 24-Week Results From the Phase IIb, Dose-Range Finding DOMINO Study - (10/25/23)   Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + Dolutegravir as a 2-Drug Regimen in Treatment-Naive Adults:24-Week Results From the Phase IIb DYNAMIC Study - (10/24/23)   Cabotegravir-Rilpivirine Long acting : Data in real life setting in a French Cohort - (10/24/23)   Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 infection switching to long-acting cabotegravir and rilpivirine - (10/24/23)   Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 for Cabotegravir + Rilpivirine Study - (10/24/23)   Safety, pharmacokinetics, and exploratory efficacy of the PD-1 inhibitor budigalimab in antiretroviral treatment-suppressed people living with HIV-1: preliminary analysis of 2 Phase 1b studies including an analytical treatment interruption - (10/24/23)   Doravirine Plus Dolutegravir 2-Drug Regimen as a Maintenance ART: results from a French cohort study - (10/24/23)   Cardiovascular Risk Assessment After Continuing or Switching to a Doravirine-based Regimen Using the Atherosclerotic Cardiovascular (ASCVD) Risk Score Model - (10/24/23)   Drivers of Satisfaction and Health-Related Quality of Life of People Living With HIV Within Europe: Findings From a Real-world Survey of People Living With HIV - (10/24/23)   Penetration of doravirine combined to raltegravir in semen: preliminary results of the DORAL switch study - (10/24/23)   New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV - press release - (10/23/23)   Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment-Experienced People with HIV after 104 Weeks of Treatment - (10/23/23)   Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities - press release - (10/23/23)   CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine FDC in treatment-naïve adults and pre-treated adults who are virologicaly suppressed, in routine clinical care, in France. One-year interim analysis results. - (10/23/23)   Real-world Effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naive People With HIV-1 and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review - (10/23/23)   Effectiveness, Safety, and Implementation Outcomes of Cabotegravir + Rilpivirine Long-Acting by Country in the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL) - (10/23/23)   SOLAR 12-Month European Results: Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF - (10/23/23)   Restarting bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after virologic rebound: a pooled analysis of studies in people with HIV-1 - Mark Mascolini (10/23/23)   Assessing Phenotypic Effect of Integrase Strand Transfer Inhibitor (INSTI)-Based Resistance Substitutions Linked to Failures on Cabotegravir - (10/23/23)   Restarting Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After Virologic Rebound: A Pooled Analysis of Studies in People With HIV-1 - (10/23/23)   Once-monthly islatravir has no meaningful effect on exposure to long-acting reversible contraceptives (LARCs) - (10/23/23)   Efficacy and safety of doravirine-based regimens by sex and race: long-term results from three phase 3 clinical trials - (10/23/23)   Investigational Studies to Understand the Decreases in Lymphocytes Seen Clinically with Islatravir (ISL) and Enabling 1the Initiation of New Clinical Trials - (10/23/23)   Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in adults with HIV-1 virologically suppressed on antiretroviral therapy: week 96 results of a randomized, open-label, phase 3 trial - (10/23/23)   Pharmacokinetics/Pharmacodynamics and Virological Activity of VH3810109 (N6LS) in Antiretroviral-Naive Viremic Adults From the Phase 2a BANNER Study - (10/23/23)   No Relevant Difference in Incident Hypertension Observed by Gender, Race, Baseline BMI, or Other Key Subgroups Through Week 96 Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials - (10/23/23)   Follow-Up of Injection Site Reactions in Clinical Studies of People Using Lenacapavir Every 6 Months for HIV Treatment - (10/23/23)   Insights and Experiences from the CAPELLA Trial: Perspectives of Healthcare Professionals and Study Coordinators on Lenacapavir Use Amongst Heavily Treatment-Experienced People with HIV - (10/23/23)   Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Antiretroviral Treatment-Naïve (TN) and -Experienced (TE) People With HIV (PWH): 3-Year Effectiveness and Safety Outcomes in the BICSTaR Observational Cohort - (10/23/23)   Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced People With HIV (PWH) With Baseline Symptoms of Depression/Anxiety and/or Insomnia in the Observational BICSTaR Study - (10/23/23)   Final Results of VICDOR: EffectiVeness of SwItChing to DOR-based Antiretroviral Therapy Under Real-world Conditions in Germany - (10/23/23)   Efficacy and safety by subgroup at week 48 after switch to doravirine/islatravir (100 mg/0.75 mg) once daily in two phase 3 trials - (10/23/23)   Efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: Week 49 results from a phase 3 trial - (10/23/23)   Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: week 48 results from a randomized, double-blind phase 3 trial - (10/23/23)   One-year frailty transitions among persons living with HIV aged 70 years or more on ART - (10/23/23)   Estimated risk of all-cause mortality [higher] and cardiovascular events in a cohort of women living with HIV and socio-demographically similar HIV-negative controls ≥40 years old - (10/22/23)   Evolution of cancers risk in PWH over 20 years and risks when immunity is restored and viral load is controlled Results from the ANRS CO4 FHDH cohort - (10/22/23)   Frailty and Quality of Life for People with HIV in Cyprus: re-visiting the cascade of care: 70% Prefrail/frail at median age 41; 44% anxiety/depression - (10/22/23)   Cognitive frailty in people living with HIV and its association with geriatric syndromes - (10/22/23)   PREDICTORS OF QUALITY OF LIFE AMONG OLDER PEOPLE LIVING WITH HIV IN KAMPALA, UGANDA: assessmemt & mgt of frailty, low physical function, malnutrition & depression could improve QOL - (10/22/23)   Uganda Elderly HIV+ Women Needs - (10/22/23)   BMI vs body composition changes to predict metabolic outcomes in people with HIV - (10/22/23)   LDL-c target achievement in people living with HIV according to individual cardiovascular risk: a retrospective single center observational study - (10/22/23)   Suicide Mortality Trends and Predictors in the PISICS Cohort of People Living with HIV in Catalonia and the Balearic Islands, Spain; PWH >50 have highest rates - (10/22/23)   Evolving trends in mortality patterns and predictors among people living with HIV in Catalonia and the Balearic Islands (Spain), 1998-2020: a multisite cohort study - Comorbidities ! - (10/22/23)   Evolution of causes of death in people living with HIV: a retrospective single center observational study - CVD & Lung Cancer leading causes of death; 80% due to Comoridites - (10/22/23)   Immunological and inflammatory profile of cerebrospinal fluid (CSF) and plasma of people living with HIV (PLWH) with or without Central Nervous System (CNS) involvement - (10/22/23)   Subclinical coronary artery disease in persons living with HIV and uninfected controls: PWH at 2-3 fold higher risk - (10/22/23)   NEW RISK FACTORS FOR FRAGILITY FRACTURES MUST BE CONSIDERED IN OLDER ADULTS WITH HIV - (10/22/23)   Neurocognitve impairment & Anxiety Symptoms May Influence The Development of Prefrailty/Frailty in Japanese PLW Aged Over 40 Years 70% PreFrailty - (10/22/23)   One-year frailty transitions among persons living with HIV aged 70 years or more on ART - (10/20/23)   "Everyone seems already satisfied because people with HIV do not die from AIDS" iCOPe Global survey - (10/20/23)   BICTEGRAVIR and DOLUTEGRAVIR have no impact on glucose levels 12 months after initiation - (10/20/23)   Cognitive trajectories among people with HIV attending a dedicated memory clinic for PLWH - (10/20/23)   Cardiovascular Risk Assessment with SCORE, SCORE2 and D.A.D in People Living with HIV with High Prevalence of Cardiovascular Risk Factors - (10/20/23)   Statins and acetylsalicylic acid (ASA) use and LDL cholesterol value below 70 mg/dl in people living with HIV (PLWH): there is a gap between European AIDS Clinical Society guidelines and clinical practice - (10/20/23)   Prevalence and predictors of non-alcoholic fatty liver disease (NAFLD) among Egyptian people living with HIV (PLHIV): A cross-sectional study - (10/20/23)   Study of the Cardiovascular Disease Risk in People Living with HIV-1 in Portugal: high risk of CVD for PLWH 40-70 Years - (10/20/23)